

Nattokinase

| | |
|-----------|---|
| Cat. No.: | HY-P2373 |
| CAS No.: | 133876-92-3 |
| Target: | Others |
| Pathway: | Others |
| Storage: | Please store the product under the recommended conditions in the Certificate of Analysis. |

Nattokinase

SOLVENT & SOLUBILITY

| | |
|----------|--|
| In Vitro | H ₂ O : 100 mg/mL (Need ultrasonic) |
| In Vivo | 1. Add each solvent one by one: PBS Solubility: 50 mg/mL (Infinity mM); Clear solution; Need ultrasonic |

BIOLOGICAL ACTIVITY

| | | |
|-------------|--|---|
| Description | Nattokinase is a potent fibrinolytic enzyme. Nattokinase can break down blood clots by directly hydrolyzing fibrin and plasmin substrate. Nattokinase can be used for the research of cardiovascular diseases ^[1] . | |
| In Vitro | Nattokinase dissolves 94% blood clot at ten minutes and degrades the fibrin clot after two hours of incubation ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. | |
| In Vivo | Nattokinase (150-250 mg/kg; oral gavage twice daily for 2 days) exhibits fibrinolytic activity and dissolves blood clots in vivo ^[3] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. | |
| | Animal Model: | Sprague-Dawley (SD) rats (180-220 g) are injected k-Carrageenan ^[3] |
| | Dosage: | 150, 250 mg/kg |
| | Administration: | Oral gavage twice daily for 2 days |
| | Result: | Increased the plasma concentration of fibrin/fibrinogen degradation products (FDPs) and D-Dimer in a dose-dependent manner. Decreased the fraction of the vessel cross section occupied by thrombosis. |

REFERENCES

[1]. Weng Y, et, al. Nattokinase: An Oral Antithrombotic Agent for the Prevention of Cardiovascular Disease. Int J Mol Sci. 2017 Feb 28; 18(3):523.

[2]. Chandrasekaran SD, et, al. Exploring the In Vitro Thrombolytic Activity of Nattokinase From a New Strain Pseudomonas aeruginosa CMSS. Jundishapur J Microbiol. 2015 Oct 26; 8(10): e23567.

[3]. Xu J, et, al. Thrombolytic effects in vivo of nattokinase in a carrageenan-induced rat model of thrombosis. Acta Haematol. 2014; 132(2): 247-53.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA